申请人:HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD.
公开号:US10792283B2
公开(公告)日:2020-10-06
The present disclosure provides selective phosphoinositide 3-kinase inhibitors of formula (A), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more P13K isoforms, such as PI3K delta (PI3Kδ). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase inhibitors using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase activity.
本公开提供了式(A)的选择性磷酸肌醇 3-激酶抑制剂或其药学上可接受的盐。这些化合物可用于治疗由一种或多种 P13K 同工酶(如 PI3K delta (PI3Kδ))介导的病症。本公开进一步提供了使用这些化合物抑制磷脂酰肌醇3-激酶抑制剂的方法,用于治疗与磷脂酰肌醇3-激酶活性有关的疾病。